{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:58:17Z","timestamp":1783511897856,"version":"3.55.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08049"],"award-info":[{"award-number":["20K08049"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.brachy.2022.12.001","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T15:04:04Z","timestamp":1672671844000},"page":"293-303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biochemical outcomes and toxicities in young men with prostate cancer after permanent iodine-125 seed implantation: Prospective cohort study in 6662 patients"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2208-8897","authenticated-orcid":false,"given":"Norihisa","family":"Katayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4808-7147","authenticated-orcid":false,"given":"Atsunori","family":"Yorozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2360-2915","authenticated-orcid":false,"given":"Takashi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Higashide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Masui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2022.12.001_bib0001","series-title":"Perez and Brady\u02bcs principles and practice of radiation oncology","first-page":"1560","article-title":"Low-risk prostate cancer","author":"Perez","year":"2019"},{"key":"10.1016\/j.brachy.2022.12.001_bib0002","series-title":"Perez and Brady\u02bcs principles and practice of radiation oncology","first-page":"1602","article-title":"Management of intermediate- and high-risk prostate cancer: what do we know?","author":"Roach","year":"2019"},{"key":"10.1016\/j.brachy.2022.12.001_bib0003","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ijrobp.2010.07.2004","article-title":"Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials","volume":"81","author":"Hamstra","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0004","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jclinpath-2015-202993","article-title":"Young-age prostate cancer","volume":"68","author":"Hussein","year":"2015","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0005","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.ijrobp.2009.06.052","article-title":"Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer","volume":"77","author":"Burri","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0006","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.juro.2008.11.122","article-title":"Long-term outcomes in younger men following permanent prostate brachytherapy","volume":"181","author":"Shapiro","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0007","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00130404-200607000-00009","article-title":"The effect of age on prostate implantation results","volume":"12","author":"Peschel","year":"2006","journal-title":"Cancer J"},{"key":"10.1016\/j.brachy.2022.12.001_bib0008","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10147-014-0704-4","article-title":"Nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS)","volume":"20","author":"Saito","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0009","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.brachy.2019.03.008","article-title":"Biochemical outcomes and predictive factors by risk group after permanent iodine-125 seed implantation: prospective cohort study in 2316 patients","volume":"18","author":"Katayama","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.001_bib0010","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s10147-018-1309-0","article-title":"Nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (JPOPS): first analysis on survival","volume":"23","author":"Ito","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0011","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2005.07.981","article-title":"Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results","volume":"64","author":"Stock","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0012","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0013","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/iju.13358","article-title":"Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database","volume":"24","author":"Okihara","year":"2017","journal-title":"Int J Urol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0014","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. Common terminology criteria for adverse events version 3.0. NCI CTEP Website. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed March 14, 2022."},{"key":"10.1016\/j.brachy.2022.12.001_bib0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1586\/era.10.211","article-title":"Predictors in the outcome of 125I brachytherapy as monotherapy for prostate cancer","volume":"11","author":"Hinnen","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.brachy.2022.12.001_bib0016","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00345-013-1148-6","article-title":"PSA-nadir at 1 year as a sound contemporary prognostic factor for low-dose-rate iodine-125 seeds brachytherapy","volume":"32","author":"Reis","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0017","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1464-410X.2006.06248.x","article-title":"Brachytherapy in men aged \u226454 years with clinically localized prostate cancer","volume":"98","author":"Merrick","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2022.12.001_bib0018","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.urology.2009.04.101","article-title":"Median 5 Year follow-up of 125Iodine brachytherapy as monotherapy in men aged \u2264 55 years with favorable prostate cancer","volume":"75","author":"G\u00f3mez-Iturriaga Pi\u00f1a","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2022.12.001_bib0019","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.urology.2012.08.112","article-title":"Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up","volume":"81","author":"Buckstein","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2022.12.001_bib0020","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1464-410X.2012.11663.x","article-title":"Favourable long-term outcomes with brachytherapy-based regimens in men \u226460 years with clinically localized prostate cancer","volume":"111","author":"Kollmeier","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2022.12.001_bib0021","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00066-017-1238-2","article-title":"Long-term outcomes in patients younger than 60 years of age treated with brachytherapy for prostate cancer","volume":"194","author":"Prada","year":"2018","journal-title":"Strahlentherapie und Onkol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bju.13946","article-title":"Long-term oncological outcomes and toxicity in 597 men aged \u226460 years at time of low-dose-rate brachytherapy for localised prostate cancer","volume":"121","author":"Langley","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2022.12.001_bib0023","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brachy.2018.12.005","article-title":"Long-term oncological and functional outcomes support use of low-dose-rate brachytherapy with or without external beam radiation in young men (\u226460 years) with localized prostate cancer","volume":"18","author":"Winoker","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.001_bib0024","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00345-013-1148-6","article-title":"PSA-nadir at 1 year as a sound contemporary prognostic factor for low-dose-rate iodine-125 seeds brachytherapy","volume":"32","author":"Reis","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0025","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.brachy.2017.07.016","article-title":"Low-dose-rate prostate brachytherapy: 4-8 week postimplant prostate-specific antigen a novel predictor of biochemical failure-free survival","volume":"16","author":"Callaghan","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.001_bib0026","first-page":"e276","article-title":"Development of ProCaRS clinical nomograms for biochemical failure-free survival following either low-dose rate brachytherapy or conventionally fractionated external beam radiation therapy for localized prostate cancer","volume":"7","author":"Warner","year":"2015","journal-title":"Cureus"},{"key":"10.1016\/j.brachy.2022.12.001_bib0027","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.ijrobp.2010.04.038","article-title":"10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1100 Patients","volume":"80","author":"Crook","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0028","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jjco\/hys240","article-title":"Comparison of preplanning and intraoperative planning for I-125 prostate brachytherapy","volume":"43","author":"Yoshida","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0029","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1002\/cncr.26183","article-title":"Impact of race on biochemical disease recurrence after prostate brachytherapy","volume":"117","author":"Yamoah","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.brachy.2022.12.001_bib0030","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.ijrobp.2010.01.005","article-title":"Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy","volume":"79","author":"Taira","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0031","first-page":"588","article-title":"Obesity is not predictive of overall survival following permanent prostate brachytherapy","volume":"30","author":"Merrick","year":"2007","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"10.1016\/j.brachy.2022.12.001_bib0032","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.2009.09096.x","article-title":"Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent 125iodine implants","volume":"106","author":"Fern\u00e1ndez","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2022.12.001_bib0033","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.brachy.2018.08.018","article-title":"Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy","volume":"17","author":"Niwa","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.001_bib0034","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.brachy.2022.12.001_bib0035","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.21873\/anticanres.14439","article-title":"Better cancer-specific survival in younger patients with stage III colorectal cancer: a propensity score matching study from Japan","volume":"40","author":"Wang","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.brachy.2022.12.001_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12893-021-01401-1","article-title":"The outcome of young vs. old gastric cancer patients following gastrectomy: a propensity score matching analysis","volume":"21","author":"Cheng","year":"2021","journal-title":"BMC Surg"},{"key":"10.1016\/j.brachy.2022.12.001_bib0037","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00595-019-01934-2","article-title":"Long-term outcomes of colorectal cancer surgery for elderly patients: a propensity score-matched analysis","volume":"50","author":"Sakamoto","year":"2020","journal-title":"Surg Today"},{"key":"10.1016\/j.brachy.2022.12.001_bib0038","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/jso.25457","article-title":"Effect of younger age on survival outcomes in T1N0M0 breast cancer: a propensity score matching analysis","volume":"119","author":"Zhong","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0039","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ases.12719","article-title":"Single-port laparoscopic colectomy in elderly patients with colon cancer: a propensity score-matched comparison with younger patients","volume":"13","author":"Hirano","year":"2020","journal-title":"Asian J Endosc Surg"},{"key":"10.1016\/j.brachy.2022.12.001_bib0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00384-018-3028-4","article-title":"Oncologic outcome of colorectal cancer patients over age 80: a propensity score-matched analysis","volume":"33","author":"Oh","year":"2018","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.brachy.2022.12.001_bib0041","first-page":"1","article-title":"Pathological characteristics of prostate cancer in men aged < 50 years treated with radical prostatectomy: a multi-centre study in Korea","volume":"34","author":"Chung","year":"2019","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.brachy.2022.12.001_bib0042","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bju.14586","article-title":"Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook","volume":"122","author":"Gielchinsky","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2022.12.001_bib0043","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.brachy.2019.11.003","article-title":"Favorable preservation of erectile function after prostate brachytherapy for localized prostate cancer","volume":"19","author":"Bazinet","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.001_bib0044","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ijir.2013.3","article-title":"Proposal for a predictive model of erectile function after permanent (125)I prostate brachytherapy for localized prostate cancer","volume":"25","author":"Huyghe","year":"2013","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.brachy.2022.12.001_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/and.14070","article-title":"The interaction between inflammation, urinary symptoms and erectile dysfunction in early-stage prostate cancer treated with brachytherapy","volume":"53","author":"Alcaidinho","year":"2021","journal-title":"Andrologia"},{"key":"10.1016\/j.brachy.2022.12.001_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-4190-23-2","article-title":"Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer","volume":"23","author":"Njomnang Soh","year":"2013","journal-title":"Basic Clin Androl"},{"key":"10.1016\/j.brachy.2022.12.001_bib0047","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.juro.2012.09.086","article-title":"A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy","volume":"189","author":"Matsushima","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0048","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ijrobp.2011.11.004","article-title":"Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy","volume":"82","author":"Whaley","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0049","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1464-410X.2007.07016.x","article-title":"Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at \u22657 years of follow-up","volume":"100","author":"Cesaretti","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2022.12.001_bib0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijrobp.2004.12.056","article-title":"Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important?","volume":"63","author":"Macdonald","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0051","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.urology.2005.03.045","article-title":"Cross-sectional analysis of sexual function after prostate brachytherapy","volume":"66","author":"Finney","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2022.12.001_bib0052","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.brachy.2015.12.011","article-title":"Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy","volume":"15","author":"Eriguchi","year":"2016","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.001_bib0053","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ijrobp.2015.02.047","article-title":"Long-term efficacy and toxicity of low-dose-rate 125I prostate brachytherapy as monotherapy in low-, intermediate-, and high-risk prostate cancer","volume":"92","author":"Kittel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0054","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.brachy.2014.02.002","article-title":"Single-nucleotide polymorphisms studied for associations with urinary toxicity from 125I prostate brachytherapy implants","volume":"13","author":"Usmani","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.001_bib0055","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijrobp.2014.06.037","article-title":"Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals","volume":"90","author":"Keyes","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0056","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1200\/JCO.2006.07.9954","article-title":"Patient and treatment factors associated with complications after prostate brachytherapy","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0057","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijrobp.2013.04.047","article-title":"Novel parameter predicting grade 2 rectal bleeding after iodine-125 prostate brachytherapy combined with external beam radiation therapy","volume":"87","author":"Shiraishi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0058","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.brachy.2019.03.007","article-title":"Genitourinary toxicity after permanent iodine-125 seed implantation: the nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS)","volume":"18","author":"Tanaka","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.001_bib0059","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/iju.12050","article-title":"Predictive factors for acute and late urinary toxicity after permanent interstitial brachytherapy in Japanese patients","volume":"20","author":"Tanimoto","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijrobp.2011.02.037","article-title":"Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis","volume":"81","author":"Zilli","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2007.12.002","article-title":"Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy","volume":"7","author":"Zelefsky","year":"2008","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.001_bib0062","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2020.04.038","article-title":"A biochemical definition of cure after brachytherapy for prostate cancer","volume":"149","author":"Crook","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2022.12.001_bib0063","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bju.14841","article-title":"Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis","volume":"124","author":"Mazzone","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2022.12.001_bib0064","first-page":"1","article-title":"Secondary bladder cancer during long-term follow-up after iodine-125 permanent seed implantation for localized prostate cancer","author":"Ozawa","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2022.12.001_bib0065","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijrobp.2007.12.043","article-title":"Second primary cancer after radiotherapy for prostate cancer-A SEER analysis of brachytherapy versus external beam radiotherapy","volume":"72","author":"Abdel-Wahab","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2022.12.001_bib0066","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/j.1464-410X.2012.11385.x","article-title":"Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention","volume":"110","author":"Zelefsky","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2022.12.001_bib0067","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/cncr.22083","article-title":"Cancer incidence after localized therapy for prostate cancer","volume":"107","author":"Moon","year":"2006","journal-title":"Cancer"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472122003853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472122003853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:27:00Z","timestamp":1778617620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472122003853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1538472122003853"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2022.12.001","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemical outcomes and toxicities in young men with prostate cancer after permanent iodine-125 seed implantation: Prospective cohort study in 6662 patients","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2022.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}